<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01717105</url>
  </required_header>
  <id_info>
    <org_study_id>GGCP 048-10</org_study_id>
    <secondary_id>GGC-CPN-2010-01</secondary_id>
    <nct_id>NCT01717105</nct_id>
  </id_info>
  <brief_title>Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients</brief_title>
  <official_title>Observational Post-authorization Prospective Study to Characterize the Incidence of Epidermal Growth Factor Receptor (EGFR) Mutation Positive and Advanced Non-small Cell Lung Cancer Patients and Their Clinical Management in Galicia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Gallego de Cancer de Pulmon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dynamic Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Gallego de Cancer de Pulmon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study has been designed in order to characterize the incidence of patients with
      advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR)
      positive mutations and their clinical management in Galicia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with epidermal growth factor receptor (EGFR) positive mutation among advanced or metastatic non-small-cell lung cancer (NSCLC) patients in Galicia</measure>
    <time_frame>10 months (recruitment period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epidermal growth factor receptor (EGFR) mutational status in tumor tissue (primary tumor or metastatic samples) and plasma samples at screening</measure>
    <time_frame>1 day (Screening Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of epidermal growth factor receptor (EGFR) mutations: deletion in exon 19, point mutation at codon 858 (L858R) or other (only for EGFR M+ patients)</measure>
    <time_frame>1 day (Screening Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescribed first line treatment (only for epidermal growth factor receptor (EGFR) M+ patients)</measure>
    <time_frame>1 day (First study visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response (only for epidermal growth factor receptor (EGFR) M+ patients)</measure>
    <time_frame>From inclusion until disease progression, death or until 9 months from the inclusion of the last patient in the study have elapsed, whichever is earlier.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (only for epidermal growth factor receptor (EGFR) M+ patients)</measure>
    <time_frame>From inclusion until the end of the study (9 months subsequent to the last patient's inclusion or until lost of follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescribed second-line treatment after progression (only for epidermal growth factor receptor (EGFR) M+ patients)</measure>
    <time_frame>1 day (Progression Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival and overall survival (only for epidermal growth factor receptor (EGFR) M+ patients)</measure>
    <time_frame>1 day (at the end of the study 9 months subsequent to the last patient's inclusion or until lost of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidermal growth factor receptor (EGFR) mutational status at disease progression in tumor tissue (primary tumor or metastatic samples) and plasma samples (only for EGFR M+ patients)</measure>
    <time_frame>1 day (Progresion Visit)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Metastatic Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>metastatic non-small cell lung cancer</arm_group_label>
    <description>Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue Plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient consultation in oncology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for patients´ screening:

          -  Patients of both sexes aged 18 or more.

          -  Histologically confirmed advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC)
             (patients stage III B unsuitable for locoregional treatment, and stage IV).

          -  Chemo- naïve patients (Non-Small-Cell Lung Cancer patients who have not received first
             line systemic cytotoxic chemotherapy).

          -  Patients with available tumoral tissue (primary tumor or metastatic area) or
             cytological samples including fine needle aspirates (primary tumor or metastatic
             area), bronchial alveolar lavage or bronchial scrapings and pleural effusion.

          -  Patients who have granted their written informed consent.

        Patients must fulfill the inclusion criteria previously mentioned and the following one in
        order to be enrolled in the study (visit 1) for the follow-up until progression or until 9
        months from the beginning of treatment have elapsed:

        Inclusion Criteria for patients´ follow-up

          -  Patients with documented positive mutation in epidermal growth factor receptor (EGFR)
             (M+).

        Exclusion Criteria:

          -  Combined histology of non-small cell and small cell lung cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Vázquez Estévez, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Grupo Gallego de Cáncer de Pulmón (GGCP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complexo Hospitalario Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Orense</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral-Cíes</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Povisa</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucus Augusti Hospital</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2012</study_first_submitted>
  <study_first_submitted_qc>October 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>Epidermal growth factor receptor (EGFR) positive mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

